Year All202420232022202120202019201820172016201520142013201220112010200920082007200620052004200320022001200019991998 BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Dec 04, 2024 Read More BioCryst Launches ORLADEYO® (berotralstat) in Ireland Nov 18, 2024 Read More BioCryst to Present at Upcoming Investor Conferences Nov 06, 2024 Read More BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Nov 05, 2024 Read More BioCryst Reports Third Quarter 2024 Financial Results and Provides Business Update Nov 04, 2024 Read More BioCryst Presents New Real-World Evidence Showing High Adherence and Persistence Rates with ORLADEYO® (berotralstat) Oct 24, 2024 Read More BioCryst to Report Third Quarter 2024 Financial Results on November 4 Oct 21, 2024 Read More BioCryst to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations After Starting ORLADEYO® (berotralstat) Oct 14, 2024 Read More BioCryst to Present New Real-World Evidence on Long-Term Prophylaxis in HAE, including ORLADEYO® (berotralstat), at the American College of Allergy, Asthma & Immunology 2024 Annual Scientific Meeting Oct 10, 2024 Read More BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Oct 03, 2024 Read More
BioCryst Reports Third Quarter 2024 Financial Results and Provides Business Update Nov 04, 2024 Read More
BioCryst Presents New Real-World Evidence Showing High Adherence and Persistence Rates with ORLADEYO® (berotralstat) Oct 24, 2024 Read More
BioCryst to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations After Starting ORLADEYO® (berotralstat) Oct 14, 2024 Read More
BioCryst to Present New Real-World Evidence on Long-Term Prophylaxis in HAE, including ORLADEYO® (berotralstat), at the American College of Allergy, Asthma & Immunology 2024 Annual Scientific Meeting Oct 10, 2024 Read More